Press Releases

The Co-operators and BDC Capital co-lead investment that will expand AI-driven infectious disease global early warning system TORONTO, August 7, 2019 /PRNewswire/ - BlueDot, a digital health company that uses big data analytics to track and anticipate the spread of the world's most dangerous infectious diseases, announced today that i

GERMANTOWN, Md., Aug. 7, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR) ("Neuralstem" or the  Company") today announced that on August 6, 2019, it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that the Nasdaq Hearings Panel (the "Panel") has granted the Company

NEW HAVEN, Conn., Aug. 7, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases today reported completion of enrollment in its pivotal Phase 3 preventive treatment of migraine trial with rimegepant, its lead o

MENLO PARK, Calif., Aug. 7, 2019 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that Jessica Holmes, Brian Regan and Jim Sluck have joined the company a

ROCKVILLE, Md., Aug. 7, 2019 /PRNewswire/ -- DrFirst announced today their collaboration to deliver single sign-on (SSO) access to HIPAA compliant messaging is now available. Using DrFirst Backline and Imprivata Mobile Device Access to enable fast, secure access to shared mobile devices and applications, users can now securely communicate in real-time across care t

- Presentation scheduled for 2:30 pm ET on August 14, 2019 - VANCOUVER, Aug. 7, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and o

Second quarter 2019 revenue of $131 million Second quarter 2019 net loss of $44 million Second quarter 2019 Adjusted EBITDA1 of $60 million Generated cash flow from operating activities of $97 million in the first six months of 2019 and concluded the quarter w

NEWARK, Calif., Aug. 7, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported financial results for the second quarter ended June 30, 2019, and provided a corporate update. "We continue to make great progress in advancing our three clinical assets in diverse disease areas and are pleased with our cash runwa

PDUFA Action Date is Dec. 22, 2019 LAVAL, Quebec, Aug. 7, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the U.S. Food and Drug Administration (FDA) has accepted t

LOS ANGELES, Aug. 7, 2019 /PRNewswire/ -- Cole Moscatel and his wife Kelsea Moscatel, creators of new luxury, lifestyle platform Snob World, recently